Viability-reducing activity of Coryllus avellana L. extracts against human cancer cell lines

dc.contributor.author
Gallego, Ana
dc.contributor.author
Metón Teijeiro, Isidoro
dc.contributor.author
Baanante, Isabel V.
dc.contributor.author
Ouazzani, Jamal
dc.contributor.author
Adelin, Amelie
dc.contributor.author
Palazón Barandela, Javier
dc.contributor.author
Bonfill Baldrich, Ma. Mercedes
dc.contributor.author
Moyano Claramunt, Elisabet
dc.date.issued
2020-06-17T07:52:26Z
dc.date.issued
2020-06-17T07:52:26Z
dc.date.issued
2017-03-01
dc.date.issued
2020-06-17T07:52:26Z
dc.identifier
0753-3322
dc.identifier
https://hdl.handle.net/2445/165960
dc.identifier
668770
dc.description.abstract
The increasing rate of cancer incidence has encouraged the search for novel natural sources of anticancer compounds. The presence of small quantities of taxol and taxanes in Corylus avellana L. has impelled new potential applications for this plant in the field of biomedicine. In the present work, the cell viability-reducing activity of stems and leaves from three different hazel trees was studied against three human-derived cancer cell lines (HeLa, HepG2 and MCF-7). Both leaf and stem extracts significantly reduced viability of the three cell lines either after maceration with methanol or using taxane extraction methods. Since maceration reduced cell viability to a greater extent than taxane extraction methods, we scaled up the maceration extraction process using a method for solid/liquid extraction (Zippertex technology). Methanol leaf extracts promoted a higher reduction in viability of all cell lines assayed than stem extracts. Fractionation of methanol leaf extracts using silica gel chromatography led to the purification and identification of two compounds by HPLC-MS and NMR: (3R,5R)-3,5-dihydroxy-1,7-bis(4-hydroxyphenyl) heptane 3-O-β-d-glucopyranoside and quercetin-3-O-rhamnoside. The isolated compounds decreased viability of HeLa and HepG2 cells to a greater extent than MCF-7 cells. Our results suggest a potential use of C. avellana extracts in the pharmacotherapy of cervical cancer and hepatocarcinoma and, to a lesser extent, breast cancer.
dc.format
8 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
Elsevier Masson SAS
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1016/j.biopha.2017.02.046
dc.relation
Biomedicine & Pharmacotherapy, 2017, vol. 89, p. 565-572
dc.relation
https://doi.org/10.1016/j.biopha.2017.02.046
dc.rights
(c) Elsevier Masson SAS, 2017
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Bioquímica i Fisiologia)
dc.subject
Farmacologia
dc.subject
Química
dc.subject
Cèl·lules canceroses
dc.subject
Avellaner
dc.subject
Càncer
dc.subject
Cromatografia de líquids d'alta resolució
dc.subject
Pharmacology
dc.subject
Chemistry
dc.subject
Cancer cells
dc.subject
Hazel
dc.subject
Cancer
dc.subject
High performance liquid chromatography
dc.title
Viability-reducing activity of Coryllus avellana L. extracts against human cancer cell lines
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)